After TrucheckTM Breast, a blood test for the detection of early-stage breast cancer, has already received “Breakthrough Device Designation” from the FDA, this has now also been announced for Trublood Prostate. Both tests are CE-certified and already available in Europe.
Trublood Prostate is the first blood test that can detect early-stage prostate cancer with high sensitivity and specificity in men aged 55 and over. For this purpose, circulating tumour cells (CTCs) specific to prostate adenocarcinoma are detected in the blood. Prostate cancer can thus be detected at an early stage with an accuracy of more than 99% and without false-positive results. Trublood Prostate can help both to reduce the number of biopsies in people with benign prostate diseases and to improve the early detection rate in people with prostate cancer. Early diagnosis brings immense benefits for the patient, as curative surgery is still possible at an early stage, but virtually impossible at later stages when the cancer has already spread beyond the prostate tissue.
Please find the detailed article here: https://www.openpr.de/news/1224605/FDA-erteilt-Screeningtest-von-DCG-zur-Frueherkennung-von-Prostatakrebs-Breakthrough-Device-Designation.html